Stocks on Tech Trader

The charts, technical indicators, and signals here are generated live from Tech Trader, a fully autonomous trading system with no human intervention.

The second chart (if available) is a combination of Tech Trader with the Grok AI (from xAI) interpreting the chart and making trading decisions, including elaborate reports at the bottom explaining any given day.

Follow trades and activity on The Tech Trader Wall and Tech Trader + Grok Wall.

Tech Trader Only

(Technical Analysis + Trades by Tech Trader)

Tech Trader + Grok

(Grok trading on top of charts by Tech Trader, started July 14 2025)

Grok's Analysis

2026-05-08	CASH
Summary: Recent weakness after the May 1 FDA panel rejection on camizestrant and post-earnings drift leaves AZN in a choppy downtrend with no strong reversal signal. Price has slid from the April highs near 205 to the current 183 area, with the last few sessions showing low-volume consolidation around 182-184 after your May 1 exit at 184.74. Multiple quick round-trips in March-April already produced losses, and the chart lacks a clean breakout or volume surge to justify jumping back in now. Long-term analyst targets remain higher, but for a 7+ day hold the risk of further whipsaw outweighs any modest upside until a clearer catalyst or support test appears. Staying flat preserves capital until the setup improves.
2026-05-07	CASH
Summary: Recent price action around 182-185 shows sideways churning after the April earnings dip and mixed FDA news, with no strong breakout or trend to justify a new position. ...
2026-05-05	CASH
Summary: AZN keeps sliding lower after the FDA setback, so cash is the smart move right now to skip more whipsaws. ...
2026-05-04	CASH
Summary: After the FDA panel's rejection of camizestrant and the stock's fresh breakdown below recent support, staying in cash avoids another quick loss like the ones from our March-April trades. ...
2026-05-01	CASH
Summary: Exiting the long to cash after today's FDA panel rejection on camizestrant adds downside pressure amid an already weakening chart. ...
2026-04-30	CASH
Summary: ...
2026-04-29	CASH
Summary: ...
2026-04-27	CASH
Summary: ...
2026-04-24	SOLD
Summary: ...
2026-04-23	HOLD LONG
Summary: ...
2026-04-22	HOLD LONG
Summary: ...
2026-04-21	HOLD LONG
Summary: ...
2026-04-20	HOLD LONG
Summary: ...
2026-04-17	HOLD LONG
Summary: ...
2026-04-16	HOLD LONG
Summary: ...
2026-04-15	HOLD LONG
Summary: ...
2026-04-14	HOLD LONG
Summary: ...
2026-04-13	HOLD LONG
Summary: ...
2026-04-10	HOLD LONG
Summary: AZN looks strong technically and fundamentally right nowâ€”holding the long from $188.42 makes sense with the uptrend, positive trial data, and repeated analyst upgrades. ...
2026-04-09	HOLD LONG
Summary: ...
2026-04-08	HOLD LONG
Summary: ...
2026-04-07	HOLD LONG
Summary: AZN daily chart confirms bullish continuation with higher highs/lows since our 3/27 entry at 188.42, strong breakout above 200 to 204 highs, and only minor pullback on 4/7 holding the uptrend. ...
2026-04-06	HOLD LONG
Summary: We're staying long AZN from our 3/27/26 entry at $188.42 as the daily chart shows a strong uptrend with higher highs and closes pushing above $203 on healthy momentum. ...
2026-04-02	HOLD LONG
Summary: AZN looks strong in a clear uptrend after positive COPD trial news, holding above key EMAs with solid momentum so we stay long from our 188.42 entry on 3/27. ...
2026-04-01	HOLD LONG
Summary: ...
2026-03-31	HOLD LONG
Summary: ...
2026-03-30	HOLD LONG
Summary: Holding our long from 188.42 as AZN pushes to new highs near 195 on strong momentum with no negative news or reversal signals....
2026-03-27	BUY
Summary: ...
2026-03-26	SOLD
Summary: Although we were holding the long from 185.78 expecting the recovery to continue, today's higher-volume selloff to 183.46 retesting lows plus a reported LAPSUS$ data breach changes the picture, so we're exiting to cash....
2026-03-25	HOLD LONG
Summary: Holding the long from 185.78 as AZN extends its recovery to 187.18 with a higher high today and supportive news flow on pipeline and expansions....
2026-03-24	BUY
Summary: Although we stayed in cash waiting for clearer reversal confirmation after the recent breakdown, today's strong rebound from 182.79 to close at 185.88 near the highs with improving volume provides that signal amid ongoing positive pipeline news and analyst support....
2026-03-23	CASH
Summary: Staying in cash as the modest recovery to 184.61 lacks conviction or reversal confirmation from the recent breakdown that prompted our exit, despite ongoing positive news flow on approvals and China expansion....
2026-03-20	SOLD
Summary: Although we went long yesterday on the apparent hold of support near 186 amid positive pipeline news, today's breakdown to new lows at 183.28 on higher volume invalidates that setup and triggers an exit to protect capital....
2026-03-19	BUY
Summary: Although we stayed in cash due to the recent downtrend from mid-Feb highs with lower lows, this pullback has now held support near 186 on stable closes and lighter selling volume while positive oncology news and high analyst targets ($240) shift the risk/reward higher....
2026-03-18	CASH
Summary: Continuing the cash stance from the recent downtrend assessment, today's new low and lower close on drying volume still lacks any reversal signal, keeping us on the sidelines for now....
2026-03-17	CASH
Summary: Building on yesterday's call to stay in cash due to the ongoing daily downtrend from mid-Feb highs, this minor lower close on very low volume shows no reversal or momentum shift, so we remain in cash. ...
2026-03-16	SOLD
Summary: Recent daily downtrend from mid-Feb highs above 209 to 189.90 shows lower highs/lows and short-term bearish momentum, so staying in cash avoids risk until a base forms. ...
2026-03-13	HOLD LONG
Summary: Hold long on AZN as oversold STO at 2.95 signals imminent bounce, bolstered by recent Enhertu priority review, CALQUENCE approval, and potential $17.5B Abivax acquisition rumors outweighing short-term pullback from falling resistance....
2026-03-12	BUY
Summary: Re-entering long on AZN at $192 after quick exit at $194.95 three days ago, as lower price offers better entry, new Enhertu priority review and positive analyst flip on trial halt outweigh prior technical weakness with STO oversold signaling bounce....
2026-03-11	CASH
Summary: Stay in cash as AZN remains under falling resistance with bearish MACD crossover and no compelling new bullish catalysts to justify quick re-entry after recent exit amid weakening momentum....
2026-03-10	CASH
Summary: Recent exit due to post-peak pullback from $212 to $193 with weakening momentum, bearish MACD crossover, and falling resistance trendlines persists as today's close at $195.87 remains below key resistances around $198-207, MACD still bearish, and no major new bullish news or changed circumstances to justify quick re-entry....
2026-03-09	SOLD
Summary: Exit long in AZN as the post-peak pullback from $212 to $193 signals weakening momentum with bearish MACD crossover and falling resistance trendlines, despite no major negative news. ...
2026-03-06	HOLD LONG
Summary: Hold long in AZN despite recent pullback potentially from FDA CRL on Saphnelo data errors (bearish, credible regulatory setback with high reaction potential), offset by Morgan Stanley PT raise to $109 (bullish, timely analyst upgrade likely to boost sentiment) and $15B China investment through 2030 focusing on cell therapy/radiopharma (bullish, signals strong growth commitment with material long-term impact)....
2026-03-05	HOLD LONG
Summary: Hold long in AZN amid strong uptrend post-earnings gap-up, with price in healthy pullback supported by bullish cancer drug news and growth forecasts, despite MACD bearish crossover....
2026-03-04	HOLD LONG
Summary: Hold long in AZN's sustained uptrend after massive earnings gap-up, with price rebounding from pullback amid high RSI and bullish catalysts like ongoing oncology trials, despite MACD bearish signal....
2026-03-03	HOLD LONG
Summary: Continue holding long in AZN's explosive uptrend post-earnings gap-up and NYSE listing catalyst, despite minor pullback to 201.82 with MACD bearish crossover but RSI 75 and overall bullish momentum intact; next earnings April 29, 2026, amid catalyst-rich year including oncology trials and approvals....
2026-03-02	HOLD LONG
Summary: Sustained massive uptrend after earnings-driven gap-up with bullish momentum persisting despite minor pullback and overbought signals; next earnings April 29, 2026, catalyst-rich year ahead per company outlook....
2026-02-27	HOLD LONG
Summary: Sustained massive uptrend post-earnings gap-up with high volume and bullish momentum, overbought RSI but no reversal signals yet; next earnings April 29, 2026, no major catalysts imminent....
2026-02-26	HOLD LONG
Summary: Sustained uptrend with strong momentum post-NYSE listing and positive 2026 forecasts from cancer drug demand, despite overbought RSI; next earnings April 29, 2026....
2026-02-25	HOLD LONG
Summary: Massive uptrend surges to new highs post-NYSE direct listing and positive 2026 profit forecasts from strong cancer drug demand, outweighing overbought signals; next earnings April 29, 2026....
2026-02-24	HOLD LONG
Summary: Massive uptrend persists with price surging to new all-time highs post-NYSE listing and positive oncology developments like Calquence approval, outweighing any resurfaced vaccine concerns; next earnings April 29, 2026....
2026-02-23	HOLD LONG
Summary: Strong uptrend continuation with price consolidating above key supports after massive post-earnings breakout, bolstered by positive pipeline developments and no immediate bearish catalysts; next earnings April 29, 2026....
2026-02-20	HOLD LONG
Summary: Strong post-earnings momentum from robust 2026 growth outlook and pipeline wins outweigh overbought RSI, justifying holding the long; next earnings April 29, 2026....
2026-02-19	HOLD LONG
Summary: Sustained uptrend post-ADR adjustment with strong earnings and pipeline momentum outweigh overbought signals and minor bearish news like downgrade and patent halt, justifying holding the long....
2026-02-18	HOLD LONG
Summary: Sustained explosive uptrend driven by oncology sales growth, positive earnings outlook for 2026, and no clear reversal signals despite overbought conditions justify holding the long position....
2026-02-17	HOLD LONG
Summary: Sustained bullish trend with explosive price surge post-earnings, extreme overbought RSI/MACD but no reversal signals, and positive catalysts like pipeline advancements justify holding the long position....
2026-02-13	HOLD LONG
Summary: Massive price surge post-earnings with sustained momentum and overbought but trending indicators justify holding the long despite extreme RSI levels....
2026-02-12	HOLD LONG
Summary: Strong earnings beat with upbeat 2026 guidance and NYSE listing upgrade sustain the massive bull run despite extreme overbought RSI....
2026-02-11	HOLD LONG
Summary: Massive upward momentum from NYSE listing and strong Q4 earnings beat with oncology growth guidance sustain the bull trend despite overbought RSI....
2026-02-10	HOLD LONG
Summary: Massive price surge from NYSE ordinary share listing and positive 2026 growth guidance post-earnings outweigh minor Q4 miss, with strong oncology momentum sustaining uptrend....
2026-02-09	HOLD LONG
Summary: Holding long as the NYSE listing sparked sustained upward momentum with overbought but bullish technicals, and Q4 earnings tomorrow likely to drive further gains based on positive expectations and historical reactions....
2026-02-06	HOLD LONG
Summary: Sustained massive gap up momentum from NYSE listing and positive pipeline news outweighs minor FDA delay, with earnings on Feb 10 likely to catalyze further upside....
2026-02-05	HOLD LONG
Summary: Massive 100%+ gap up on strong growth news and NYSE listing accessibility, with sustained momentum post-jump and upcoming earnings on Feb 10 potentially adding fuel....
2026-01-30	HOLD LONG
Summary: Post-earnings momentum endures with CSPC obesity drug deal ($1.2B upfront, multibillion potential) and Citi top European pharma pick at Â£170 PT....
2026-01-26	HOLD LONG
Summary: Q4 earnings beat with 15% revenue growth and raised 2026 guidance propel AZN past $109, confirming bull market....
2026-01-23	HOLD LONG
Summary: Saphnelo lupus trial success and NYSE listing confirmation boost AZN to new highs, Barclays PT hike signals upside....
2026-01-22	HOLD LONG
Summary: NYSE listing shift and Saphnelo lupus trial win spark gains, Guggenheim Buy and Barclays PT hike signal more upside....
2026-01-21	HOLD LONG
Summary: Saphnelo lupus trial success and NYSE listing announcement drive AZN gains, Barclays PT to 16,500 GBp confirms upside....
2026-01-20	HOLD LONG
Summary: Saphnelo lupus trial success and Guggenheim Buy rating ahead of Q4 earnings propel AZN to new highs....
2026-01-16	HOLD LONG
Summary: Guggenheim Buy rating and JPM $80B 2030 revenue target spotlight AZN's growth ahead of Q4 earnings....
2026-01-15	HOLD LONG
Summary: Guggenheim Buy ahead of Q4 and JPM $80B 2030 goal spotlight AZN's 2026 launch wave, breakout confirmed....
2026-01-14	HOLD LONG
Summary: Suarez US leadership for $50B investments and Guggenheim Buy ahead of Q4 fuel breakout to $102+....
2026-01-13	HOLD LONG
Summary: Rick Suarez tapped as US president to spearhead $50B investment surge, driving AZN to fresh highs with strong volume....
2026-01-12	HOLD LONG
Summary: Rick Suarez US president hire to lead $50B investment cements bullish thesis, technicals hold above key supports....
2026-01-09	HOLD LONG
Summary: Rick Suarez US president appointment for $50B investment and lupus TULIP-SC Phase 3 positivity offset minor dip, uptrend intact....
2026-01-08	HOLD LONG
Summary: Lupus drug TULIP-SC Phase 3 success and Rick Suarez named US president for $50B investment drive AZN to $97+ highs....
2026-01-07	HOLD LONG
Summary: Wall Street Zen Strong-Buy upgrade and lupus drug Phase 3 success propel AZN to $96+, top growth stock status confirmed....
2026-01-06	HOLD LONG
Summary: Sustained Zacks EPS upgrade and Wall Street Zen Strong-Buy propel AZN past $95, technicals confirm uptrend resumption....
2026-01-05	HOLD LONG
Summary: Wall Street Zen upgrades AZN to Strong-Buy amid Zacks FY2026 EPS hike to $5.06, confirming rebound from dip-buying....
2026-01-02	HOLD LONG
Summary: Zacks hikes FY2026 EPS to $5.06 and fresh stakes like My Personal CFO's 38k shares signal institutional rebound conviction....
2025-12-31	BUY
Summary: Moody Lynn $1.9M stake and JP Morgan 2026 pipeline preview signal rebound; enter long ~$92....
2025-12-30	COVERED
Summary: Ethic Inc stake hike and JP Morgan 2026 pipeline preview turn sentiment; cover short at ~$91 (1.7% gain) for now....
2025-12-29	SHORT
Summary: Latify trial flop and Andexxa US pull crush momentum; close long at ~$91 (small loss) and short below $92 support....
2025-12-26	BUY
Summary: AZN is in a clear uptrend with EMA above SMA and price above both, showing strong momentum from recent highs and positive oncology developments, offering a high-confidence entry at current levels around $92.71 for a multi-week hold targeting potential resistance near $95-97 based on historical patterns, with re-entry justified by price breaking prior highs and sustained buying pressure invalidating previous fade concerns....
2025-12-24	SOLD
Summary: AZN has reached near prior highs around $93-94 in a sustained uptrend with price above rising EMA and SMA, but recent momentum fade and approach to resistance prompt exiting the long from $83.77 at current levels around $92 to lock in gains before potential pullback....
2025-12-23	HOLD LONG
Summary: AZN continues strong uptrend with price above rising EMA and SMA, recent breakout to $93 highs and recovery to $92 amid positive oncology developments and no near-term risks, justifying holding long from $83.77 targeting $95+ resistance....
2025-12-22	HOLD LONG
Summary: AZN maintains a strong uptrend with price above rising EMA and SMA, holding above $89 support amid positive oncology pipeline updates and no near-term catalysts, justifying continued long hold from $83.77 targeting new highs beyond $93....
2025-12-19	HOLD LONG
Summary: AZN continues its uptrend with price above rising EMA and SMA, holding above key $89 support trendline amid positive oncology developments like recent Imfinzi approvals and no immediate catalysts, justifying holding the long from $83.77 targeting $93+ resistance....
2025-12-17	HOLD LONG
Summary: AZN maintains a clear uptrend with price above rising EMA and SMA, recent pullback holding above key supports like the $88.60 rising trendline, bolstered by positive oncology pipeline updates and no near-term earnings risk, justifying continued hold on the long position from $83.77 targeting a retest of $93+ highs....
2025-12-15	HOLD LONG
Summary: AZN continues its strong uptrend with price above rising EMA and SMA, recent pullback finding support above key levels without capitulation, supported by positive oncology developments and no imminent earnings, justifying holding the long position from $83.77 targeting beyond recent $93+ highs....
2025-12-12	HOLD LONG
Summary: AZN maintains a clear uptrend with price above rising EMA and SMA, recent pullback holding above key supports without volume capitulation, bolstered by positive oncology pipeline momentum and no near-term earnings risk, justifying continued long hold from $83.77 targeting $94+ resistance....
2025-12-11	HOLD LONG
Summary: AZN continues its uptrend with price above rising EMA and SMA, recent pullback finding support without breaching key levels, supported by positive oncology developments and no imminent earnings, justifying hold from $83.77 targeting $94+ resistance....
2025-12-09	HOLD LONG
Summary: AZN maintains a solid uptrend with price above rising EMA and SMA, recent pullback from $93+ finding support around $90 without breaching key levels, bolstered by positive oncology pipeline news and no near-term earnings, supporting continued hold from $83.77 targeting $94+ resistance....
2025-12-05	HOLD LONG
Summary: AZN remains in a clear uptrend with price above rising EMA and SMA, recent pullback to $90.1 finding support near prior highs without breaking key levels, supported by positive oncology developments and no imminent earnings risk, justifying holding the long position from $83.77 targeting $94+ resistance....
2025-12-04	HOLD LONG
Summary: AZN continues in a strong uptrend with price above rising EMA and SMA, recent support at $90 holding firm amid positive oncology pipeline updates and no near-term earnings, supporting holding the long from $83.77 targeting resistance near $94....
2025-12-03	HOLD LONG
Summary: AZN maintains a clear uptrend with price above rising EMA and SMA, recent pullback finding support near $90 without breaking key levels, supported by positive oncology developments and no imminent earnings risk, justifying holding the long position from $83.77 for further upside potential....
2025-12-02	HOLD LONG
Summary: AZN remains in a clear uptrend with price above rising EMA and SMA, recent pullback from $93.32 finding support near $90 without violating key levels, bolstered by positive oncology pipeline news and no near-term earnings risk, supporting holding the long position from $83.77 for further upside....
2025-12-01	HOLD LONG
Summary: AZN maintains a clear uptrend with price above rising EMA and SMA, recent pullback from $93.32 high finding support near $90 without breaking key levels, supported by positive oncology developments and no imminent earnings risk, justifying holding the profitable long from $83.77....
2025-11-28	HOLD LONG
Summary: AZN remains in a robust uptrend with price at multi-month highs near $93, EMA above SMA and both rising, supported by positive oncology pipeline momentum and no near-term earnings or resistance prompting an exit from the profitable long at $83.77....
2025-11-26	HOLD LONG
Summary: AZN maintains a strong uptrend with price at new highs above $93, supported by positive momentum, oncology advancements, and no immediate resistance or catalysts warranting an exit from the profitable long position entered at $83.77....
2025-11-25	HOLD LONG
Summary: AZN continues its robust uptrend with price surging to new highs above $93 on strong volume and positive momentum indicators, supported by recent oncology pipeline advancements and no near-term resistance or catalysts justifying an exit from the long position entered at $83.77....
2025-11-24	HOLD LONG
Summary: AZN maintains a strong uptrend with price breaking to new highs above $91, supported by positive oncology developments and no immediate resistance or catalysts warranting an exit from the existing long position entered at $83.77....
2025-11-21	HOLD LONG
Summary: AZN continues its robust uptrend with price well above rising EMA and SMA, recent breakout to new highs around $91 supported by positive oncology pipeline momentum and no near-term catalysts or resistance breaches signaling an exit....
2025-11-20	HOLD LONG
Summary: AZN maintains a strong uptrend with price above rising EMA and SMA, recent closes near all-time highs around $89-90 supported by positive oncology developments and no immediate exit signals from resistance or catalysts....
2025-11-19	HOLD LONG
Summary: AZN continues its strong uptrend with price above rising EMA and SMA, recent breakout above $87.68 resistance to new highs near $90 supported by positive oncology pipeline updates and no near-term catalysts or pullback signals warranting exit from the profitable long position....
2025-11-18	HOLD LONG
Summary: AZN maintains a strong uptrend with price above rising EMA and SMA, recent highs at $89.66 supported by positive oncology developments like Imfinzi trial data and no immediate catalysts or resistance prompting exit from the profitable long entered at $83.77....
2025-11-17	HOLD LONG
Summary: AZN continues in a strong uptrend with price above rising EMA and SMA, recent breakout above $87.68 resistance on positive oncology pipeline momentum and no near-term catalysts warranting exit from the profitable long at $83.77 after 7 bars....
2025-11-13	HOLD LONG
Summary: AZN maintains a strong uptrend with price above rising EMA and SMA, recent breakout above resistance on positive oncology updates like datopotamab deruxtecan data, no immediate catalysts or earnings to warrant exiting the long from $83.77 after just a week....
2025-11-12	HOLD LONG
Summary: AZN continues strong uptrend with price above rising EMA/SMA, recent highs on positive oncology news like Imfinzi approvals, no near-term earnings or catalysts to exit existing long from $83.77....
2025-11-11	HOLD LONG
Summary: AZN maintains a strong uptrend with price above rising EMA and SMA, recent breakout to new highs on positive oncology developments and no near-term catalysts warranting exit....
2025-11-10	HOLD LONG
Summary: AZN continues strong uptrend with price above rising EMA/SMA, recent breakout on volume, positive oncology news, no immediate catalysts or resistance breach to exit early....
2025-11-07	HOLD LONG
Summary: AZN remains in a clear uptrend with price above rising EMA and SMA post-earnings gap-up, supported by positive oncology updates and no near-term resistance breach or catalysts warranting exit after minimal hold....
2025-11-06	BUY
Summary: AZN gapped up post-earnings on 11/6/2025 in a clear uptrend with EMA above SMA and price above both, showing strong momentum from positive Q3 results beat and oncology pipeline updates, offering high-confidence entry at $83.76 for multi-week hold targeting resistance near $87.68....
2025-11-05	CASH
Summary: AZN's trend is unclear with EMA and SMA tightly bound, price crossing them frequently without clear upward direction, and earnings tomorrow on 11/6/2025 pose volatility risk without qualifying positive history to hold through....
2025-11-04	CASH
Summary: Upcoming earnings on 11/6/2025 without qualifying positive surprise history to justify holding through, combined with unclear trend as price sits below EMA despite EMA above SMA, and no high-confidence setup for entry, prompting stay in cash to avoid volatility risk....
2025-11-03	CASH
Summary: Upcoming earnings on 11/6/2025 pose significant volatility risk without qualifying positive surprise history from the last four quarters, while the current trend is unclear with price below EMA despite being above SMA, prompting staying in cash to avoid poor entry timing near this catalyst....
2025-10-31	CASH
Summary: AZN's trend is unclear with recent price crossings of EMA/SMA and upcoming earnings on 11/6/2025 posing volatility risk, outweighing uptrend signals and positive pharma developments for a new long entry....
2025-10-30	CASH
Summary: AZN remains in a clear uptrend with price above rising EMA and SMA, but upcoming earnings on 11/6/2025 without qualifying positive history for holding through prompts staying in cash to avoid volatility, especially after recent pullback from highs near $86 amid no immediate catalysts overriding the risk. However, the trend check is strictly for entries, and while technicals are bullish with RSI at 50.39 (neutral, not overbought), MACD positive at 0.633 (with signal at 1.0567 showing some convergence but still constructive), and Slow STO K/D at 10.65/17.34 (oversold, suggesting possible bounce), the overriding factor is the earnings date on November 6, 2025, just days away....
2025-10-29	CASH
Summary: Recent pullback below EMA in unclear trend, with upcoming earnings on 11/6/2025 preventing entry due to minimum hold requirement conflicting with volatility risk....
2025-10-28	CASH
Summary: AZN's unclear trend with EMA and SMA tightly bound, price crossing them frequently without clear direction, combined with upcoming earnings on 11/6/2025 posing volatility risk, warrants staying in cash to avoid entry into a position that can't meet minimum hold without holding through unqualified earnings....
2025-10-27	CASH
Summary: AZN is in a clear uptrend with price above rising EMA and SMA, but upcoming earnings on 11/6/2025 without sufficient positive surprise history prohibit entry for a multi-week hold to avoid volatility risk....
2025-10-24	CASH
Summary: AZN remains in an uptrend with EMA above SMA and price above both, but upcoming earnings on 11/6/2025 conflict with the minimum 10-14 day hold period, as holding through is not justified by historical surprises and reactions, prompting staying in cash to avoid volatility risk....
2025-10-23	CASH
Summary: Upcoming earnings on 11/6/2025 prevent entry into a new long position given the minimum hold period and lack of qualifying earnings history to hold through, while AZN's uptrend remains intact but price is pulling back without a high-confidence dip buy setup....
2025-10-22	CASH
Summary: AZN remains in a clear uptrend with price above EMA and SMA, but recent pullback from highs near $86 lacks a high-confidence dip to support levels for re-entry so soon after exiting at $83.87 on 10/20 amid fading momentum and upcoming earnings on 11/6/2025 without qualifying positive history to hold through....
2025-10-21	CASH
Summary: AZN remains in an uptrend with price above EMA and SMA, but upcoming earnings on 11/6/2025 without qualifying positive surprise history, combined with recent pullback and no compelling new catalysts, warrant staying in cash to avoid volatility risk while awaiting a better post-earnings entry....
2025-10-20	SOLD
Summary: AZN's uptrend remains intact with price above EMA and SMA, but recent pullback below short-term support near $85 amid fading momentum and upcoming earnings on 11/6/2025 without qualifying positive surprise history prompts exit from long position to lock in small gains and avoid volatility risk....
2025-10-17	HOLD LONG
Summary: AZN remains in a clear uptrend with price above EMA and SMA, recent high-volume breakout from oncology drug approval holding above key supports without breaching resistance or exit signals, targeting potential upside to $90+ over multi-week hold....
2025-10-16	HOLD LONG
Summary: AZN continues in a strong uptrend with price above EMA and SMA, supported by recent breakout on high volume from oncology drug approval momentum, holding key supports without exit triggers near resistance....
2025-10-15	HOLD LONG
Summary: AZN maintains a clear uptrend with price above EMA and SMA, holding above recent breakout levels without breaching key supports amid positive oncology momentum and no immediate exit signals....
2025-10-14	HOLD LONG
Summary: The recent positive news on drug pricing deals and analyst buy ratings, combined with bullish technical indicators like positive MACD crossover and strong stochastic levels, support holding the long position....
2025-10-13	HOLD LONG
Summary: AZN continues strong uptrend with price above EMA/SMA, recent high-volume breakout from oncology approval holding firm without support breach, targeting $90+ amid positive pipeline momentum and no immediate catalysts for exit....
2025-10-10	HOLD LONG
Summary: AZN maintains a clear uptrend with price above EMA and SMA after recent high-volume breakout on oncology drug approval, no breaches of support or near-term catalysts warranting exit, targeting $90+ over multi-week hold....
2025-10-09	HOLD LONG
Summary: AZN continues strong uptrend with price above EMA/SMA after high-volume breakout on oncology drug approval, holding gains toward $90+ target with no near-term catalysts or resistance breaches....
2025-10-08	HOLD LONG
Summary: AZN remains in a clear uptrend with price above EMA and SMA, recent high-volume breakout on positive drug approval news holding strong despite today's bearish candle, targeting $90+ over multi-week horizon with no immediate catalysts....
2025-10-07	HOLD LONG
Summary: AZN maintains a strong uptrend with price above both EMA and SMA, recent high-volume breakout to new highs on positive oncology drug news, no near-term earnings risk, holding for further upside targeting $90+ over multi-week horizon....
2025-10-06	HOLD LONG
Summary: AZN continues strong uptrend with price above EMA and SMA, recent high-volume breakout to all-time highs driven by positive oncology developments, holding for multi-week upside targeting $90+ absent near-term catalysts. ...
2025-10-03	HOLD LONG
Summary: AZN remains in a strong uptrend with price above EMA and SMA, recent high-volume breakout to new highs supported by positive oncology drug news, targeting $90+ over multi-week hold without near-term earnings risk....
2025-10-02	BUY
Summary: AZN has broken out above recent resistance on high volume with a clear uptrend (EMA above SMA, price above both), supported by positive news of a major oncology drug approval, offering a high-confidence entry at $83.63 for a multi-week hold targeting $90+....
2025-10-01	CASH
Summary: AZN's recent EMA/SMA crosses in the past month indicate an unclear trend, preventing a new long entry despite today's strong breakout to new highs on high volume, likely driven by positive news, with no immediate earnings or catalysts in the next 3 days....
2025-09-30	CASH
Summary: AZN's trend is unclear with EMA slightly below SMA and price below both after a recent pullback, lacking volume capitulation for a long entry in this pharmaceutical stock prone to sudden upside news, while shorting is prohibited....
2025-09-29	CASH
Summary: AZN remains in cash as the trend is unclear with price below both EMA and SMA despite EMA slightly above SMA, no volume capitulation for a long entry in this setup, and shorting pharmaceuticals is avoided due to high risk of sudden positive news spikes....
2025-09-26	CASH
Summary: AZN is not in a clear uptrend with price below both EMA and SMA, no volume capitulation to justify long entry in potential downtrend, and shorting pharma stocks is avoided due to high risk of sudden positive news spikes....
2025-09-25	CASH
Summary: AZN shows an unclear trend with EMA above SMA but price below both, no volume capitulation during the recent sell-off to 73.04, and oversold indicators like RSI at 29 without strong reversal signals, prompting stay in cash to avoid poor entry amid potential further downside....
2025-09-24	CASH
Summary: AZN is pulling back below both EMA and SMA in an unclear trend without volume capitulation, lacking a high-confidence uptrend dip for long entry while shorts are avoided for pharma stocks amid recent volatility and no immediate catalysts....
2025-09-23	CASH
Summary: After exiting the long position yesterday due to pullback below EMA in an unclear trend, AZN's price remains below both EMA and SMA without volume capitulation or compelling bullish signals, warranting caution and staying in cash for a better setup....
2025-09-22	SOLD
Summary: AZN has pulled back below the EMA in an unclear trend without breaking key rising support at $73, but with the position underwater from $79.54 entry amid fading momentum and no immediate catalysts, exiting to cash locks in the loss while awaiting a clearer uptrend re-entry....
2025-09-19	HOLD LONG
Summary: AZN remains in a broader uptrend with EMA above SMA, price testing but holding above rising support near $73 amid a pullback from recent highs, no volume capitulation or imminent catalysts, and positive oncology pipeline developments supporting continuation of the existing long position from $79.54 targeting potential retest of resistance around $82-83....
2025-09-18	HOLD LONG
Summary: AZN continues in a broader uptrend with EMA above SMA, price holding above key rising support near $73 without capitulation or breakdown, no imminent catalysts, and positive fundamentals like oncology advancements supporting holding the existing long from $79.54 targeting resistance around $82-83 amid recent pullback....
2025-09-16	HOLD LONG
Summary: AZN remains in an overall uptrend with EMA above SMA, price holding above rising support around $72.88 without breakdown, no immediate catalysts or bearish signals warranting exit from the existing long position at $79.54 despite the recent pullback, targeting potential resistance near $82 based on historical patterns....
2025-09-15	HOLD LONG
Summary: AZN's chart shows a pullback in an ongoing uptrend with EMA above SMA, price near rising support at ~$72.78 without breakdown, no near-term catalysts or volume capitulation signaling exit from the existing long at $79.54, targeting resistance near $82....
2025-09-12	HOLD LONG
Summary: AZN remains in a clear uptrend with EMA above SMA and price above both, no immediate catalysts or breakdowns justifying exit from the existing long position at $79.54 despite today's pullback, targeting potential retest of 82 highs....
2025-09-11	HOLD LONG
Summary: AZN continues in a strong uptrend with EMA above SMA and price above both, recent closes pushing towards 82 highs supported by positive pipeline developments in oncology and no near-term catalysts, justifying holding the long position from $79.54 targeting resistance around 85....
2025-09-10	HOLD LONG
Summary: AZN remains in a clear uptrend with EMA above SMA and price above both, recent highs around 82 supported by positive oncology pipeline news and no immediate catalysts, justifying holding the long position targeting 85 resistance....
2025-09-09	HOLD LONG
Summary: AZN continues in a strong uptrend with EMA above SMA and price above both, recent price action breaking to new highs around 81 with positive momentum from oncology pipeline updates and no near-term catalysts, supporting holding the long position targeting 85 resistance....
2025-09-08	HOLD LONG
Summary: AZN remains in a clear uptrend with EMA above SMA and price above both, recent closes pushing towards 82 with positive momentum from oncology advancements and no immediate catalysts, supporting holding the long position targeting 85 resistance....
2025-09-05	HOLD LONG
Summary: AZN continues in a strong uptrend with EMA above SMA and price above both, closing at 81.7 near all-time highs with positive momentum from recent oncology pipeline advancements and no near-term catalysts, supporting holding the existing long position targeting resistance around 85....
2025-09-04	HOLD LONG
Summary: AZN remains in a clear uptrend with EMA above SMA and price above both, closing at 81.8 near recent highs with positive momentum from oncology updates and no immediate catalysts, supporting continued long hold targeting resistance around 85....
2025-09-03	HOLD LONG
Summary: AZN continues in a strong uptrend with EMA above SMA and price above both, recent close at 82.08 showing momentum towards resistance near 85, supported by positive oncology pipeline updates and no near-term catalysts....
2025-09-02	HOLD LONG
Summary: AZN remains in a clear uptrend with EMA above SMA and price above both, no reversal signals yet, holding the existing long position from $79.54 targeting resistance near $85 amid positive pipeline momentum and no imminent catalysts....
2025-08-29	HOLD LONG
Summary: AZN continues in a strong uptrend with EMA above SMA and price above both, no reversal signals, targeting resistance near $85 amid positive oncology pipeline developments and no imminent catalysts....
2025-08-28	HOLD LONG
Summary: AZN remains in a clear uptrend with EMA above SMA and price above both, no reversal signals or volume capitulation, recent positive trial news supporting oncology pipeline, and no imminent earnings or catalysts, justifying holding the existing long from $79.54 targeting resistance near $85....
2025-08-27	HOLD LONG
Summary: AZN continues in a confirmed uptrend with EMA above SMA and price above both, no reversal signals, supportive oncology pipeline news, and targeting $85+ resistance without imminent catalysts, justifying holding the existing long from $79.54....
2025-08-26	HOLD LONG
Summary: AZN remains in a strong uptrend with EMA above SMA, price above both, positive MACD divergence, and supportive news on oncology pipeline advancements, justifying holding the existing long position from $79.54 targeting $85+ resistance amid no imminent catalysts or reversal signals....
2025-08-25	HOLD LONG
Summary: AZN continues in a clear uptrend with EMA above SMA, price above both, positive MACD, and no reversal signals or imminent earnings, supporting holding the long position from $79.54 targeting $85+ amid recent highs and supportive news....
2025-08-22	HOLD LONG
Summary: AZN maintains a strong uptrend with EMA above SMA, price above both, positive MACD, and recent highs near $81, supporting continued holding of the long position from $79.54 targeting $85 amid no immediate earnings or reversal confirmation....
2025-08-21	HOLD LONG
Summary: AZN continues its strong uptrend with EMA above SMA, price above both, positive MACD, and recent breakout to new highs near $80.50, supporting holding the long position from $79.54 for further upside targeting $85 without immediate earnings risk....
2025-08-20	HOLD LONG
Summary: AZN remains in a strong uptrend with EMA above SMA, price above both, positive MACD divergence, and recent breakout above prior resistance near $79, supporting holding the long position for multi-week upside targeting $85 without near-term earnings risk....
2025-08-19	BUY
Summary: AZN is in a clear uptrend with EMA above SMA and price above both, breaking recent highs near $79 with positive MACD and no near-term earnings risk, offering a high-confidence long entry for a multi-week hold targeting potential resistance around $85 based on historical patterns....
2025-08-18	CASH
Summary: AZN is in a clear uptrend with EMA above SMA and price above both, but the current price at 79.25 is near recent highs and not a dip, so staying in cash to wait for a better entry on a pullback while avoiding re-entry too soon after the recent exit at 75.34....
2025-08-15	CASH
Summary: AZN is in a clear uptrend with EMA above SMA and price above both, but current levels are at recent highs without a dip for entry, so staying in cash to wait for a better pullback opportunity....
2025-08-14	CASH
Summary: AZN is in a clear uptrend with EMA above SMA and price above both, but currently at highs near resistance around $78.21 with elevated RSI and STO, suggesting waiting for a dip to enter long for better risk/reward on a multi-week hold....
2025-08-13	CASH
Summary: AZN is in an uptrend with EMA above SMA and price above both, but it's nearing strong resistance at $78.21 after a recent exit, so staying in cash to wait for a dip offering better entry with favorable risk/reward....
2025-08-12	SOLD
Summary: AZN has reached the $75.12 resistance level in a continuing uptrend, prompting an exit from the long position entered at $73.98 to lock in gains near resistance while avoiding potential pullback, with no immediate catalysts and next earnings on November 6, 2025....
2025-08-11	HOLD LONG
Summary: AZN continues in a clear uptrend with EMA above SMA and price above both, holding the long position from $73.98 targeting $78 resistance, supported by oncology advancements and no near-term catalysts, with next earnings on November 6, 2025....
2025-08-08	HOLD LONG
Summary: AZN remains in a clear uptrend with EMA above SMA and price above both, supported by recent Q2 2025 earnings beat and oncology pipeline advancements, justifying continued holding of the long position from $73.98 targeting $78 resistance over the next 1-2 weeks despite minor pullback, with next earnings on November 6, 2025....
2025-08-07	HOLD LONG
Summary: AZN continues in a solid uptrend with EMA above SMA and price above both, bolstered by recent strong H1 2025 earnings, oncology pipeline progress like IMFINZI priority review, and $50B US investment plans, supporting holding the long position from $73.98 targeting $78 resistance over the next 1-2 weeks with no immediate catalysts....
2025-08-06	HOLD LONG
Summary: AZN remains in a clear uptrend with EMA above SMA and price above both, supported by strong H1 2025 earnings, positive oncology pipeline updates including IMFINZI priority review and Gefurulimab Phase III success, and the $50B US investment plan, justifying continued holding of the long position from $73.98 targeting $78 resistance over the next 1-2 weeks amid favorable fundamentals and no immediate catalysts....
2025-08-05	HOLD LONG
Summary: AZN maintains a clear uptrend with EMA above SMA and price above both, bolstered by strong Q2 2025 earnings beat, positive oncology pipeline updates like IMFINZI priority review, and $50B US investment announcement, justifying holding the long position from $73.98 for at least 10-14 days targeting $78 resistance amid ongoing recovery....
2025-08-04	HOLD LONG
Summary: AZN continues in a clear uptrend with EMA above SMA and price above both, supported by strong Q2 2025 earnings, positive guidance, and $50B US investment news, justifying holding the long position from $73.98 targeting $78 resistance amid recent pullback recovery....
2025-08-01	HOLD LONG
Summary: AZN maintains a clear uptrend with EMA above SMA and price above both, supported by strong Q2 2025 earnings beat, unchanged positive guidance, and $50B US investment plans, justifying continued long hold from $73.98 entry targeting $78 resistance despite minor pullback....
2025-07-31	HOLD LONG
Summary: AZN remains in a clear uptrend with EMA above SMA and price above both, despite today's pullback, supported by strong Q2 earnings, positive Gefurulimab trial, and $50B US investment plans, justifying continued long hold targeting $78 resistance. ...
2025-07-29	BUY
Summary: AZN shows a clear uptrend with EMA above SMA and price above both, supported by recent Q2 earnings beat on revenue, positive Phase 3 trial results for Gefurulimab, and reaffirmed 2025 outlook, offering a high-confidence entry post-earnings pullback for a multi-week hold targeting resistance near $78....
2025-07-28	CASH
Summary: AZN's trend is unclear with EMA and SMA tightly bound and recently crossing, while earnings tomorrow on July 29, 2025, introduce high volatility risk without compelling bullish catalysts to justify entry today....
2025-07-25	CASH
Summary: Trend is unclear with tightly bound EMA/SMA and frequent price crossings without volume capitulation, combined with upcoming earnings on July 29 introducing volatility risk, warranting staying in cash to avoid poor entry before the event....
2025-07-24	CASH
Summary: AZN's trend is unclear with EMA slightly below SMA and price above both, while upcoming earnings on July 29, 2025, pose volatility risk without overriding catalysts to justify entry and holding through....
2025-07-23	CASH
Summary: AZN's trend is unclear with EMA below SMA in a tight range, and upcoming earnings on July 29, 2025, introduce volatility risk without overriding catalysts to justify entry before the event....
2025-07-22	SOLD
Summary: Upcoming AZN earnings on July 25, 2025, pose volatility risk without overriding bullish catalysts to justify holding through, especially in unclear trend with EMA below SMA, prompting exit from long at small gain to preserve capital for better post-earnings setup....
2025-07-21	HOLD LONG
Summary: Holding long position as per minimum hold period, with price near support and oversold indicators suggesting potential bounce, despite unclear trend and no immediate catalysts invalidating the trade....
2025-07-18	BUY
Summary: AZN is oversold with RSI at 40, STO K at 22 near lower Bollinger Band, showing potential bounce from recent lows around $68-69, supported by strong fundamentals and positive pipeline developments for a multi-week hold....
2025-07-17	SOLD
Summary: AZN broke below key rising support at ~70 with bearish MACD crossover and weakening momentum, compounded by recent negative trial rumors and sector headwinds, prompting exit from long position after minimal hold to preserve capital....
2025-07-16	BUY
Summary: AZN holds rising support at ~70 with converging MACD signaling potential upside, supported by strong fundamentals and positive oncology pipeline news, offering favorable risk/reward for multi-week hold....